Work

Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.1018

Authors: Priyanka Sharma, Vandana Gupta Abramson, Anne O'Dea, Harsh B Pathak, Ziyan Y. Pessetto, Yen Y. Wang, Karissa Finke, Marc Steven Hoffmann, Manana Elia, Sharon Lewis, Jecinta Scott, Jilliann De Jong, Julia Urban, Jaimie Heldstab, Stephanie LaFaver, Stephen K. Williamson, Greg Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin

Institutions: University of Kansas Medical Center, Vanderbilt University, University of Kansas, The University of Kansas Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2806936224

Cites:

Cited by: 24

Related to: 10